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Abstract
Background: Parkinson’s disease (PD) is characterized by the selective loss of dopaminergic neurons in the
substantia nigra (SN), resulting in tremor, rigidity, and bradykinesia. Although the etiology is unknown, insight into
the disease process comes from the dopamine (DA) derivative, 6-hydroxydopamine (6-OHDA), which produces
PD-like symptoms. Studies show that 6-OHDA activates stress pathways, such as the unfolded protein response
(UPR), triggers mitochondrial release of cytochrome-c, and activates caspases, such as caspase-3. Because the
BH3-only protein, Puma (p53-upregulated mediator of apoptosis), is activated in response to UPR, it is thought to
be a link between cell stress and apoptosis.
Results: To test the hypothesis that Puma serves such a role in 6-OHDA-mediated cell death, we compared the
response of dopaminergic neurons from wild-type and Puma-null mice to 6-OHDA. Results indicate that Puma is
required for 6-OHDA-induced cell death, in primary dissociated midbrain cultures as well as in vivo. In these
cultures, 6-OHDA-induced DNA damage and p53 were required for 6-OHDA-induced cell death. In contrast, while
6-OHDA led to upregulation of UPR markers, loss of ATF3 did not protect against 6-OHDA.
Conclusions: Together, our results indicate that 6-OHDA-induced upregulation of Puma and cell death are
independent of UPR. Instead, p53 and DNA damage repair pathways mediate 6-OHDA-induced toxicity.
Background
PD is a common neurodegenerative disorder character-
ized by the progressive loss of dopaminergic neurons in
the SN resulting in the loss of dopaminergic innervation
to the striatum. Although the molecular mechanisms
are unknown, oxidative stress, mitochondrial dysfunc-
tion and endoplasmic reticulum (ER) stress have all
been implicated in the etiology of this disorder [1,2].
The neurotoxin 6-OHDA is a hydroxylated analog of
DA that is commonly used to model dopaminergic
degeneration both in vitro and in vivo [3]. Like DA, 6-
OHDA quickly oxidizes to form a variety of free radical
species, including hydrogen peroxide, superoxide and
hydroxyl radicals [4]. Toxin-induced free radical forma-
tion can be blocked by antioxidants, such as N-acetyl-L-
cysteine (NAC), MnTBAP, or C3 carboxyfullerene [5,6],
which prevent downstream toxic sequelae such as oxida-
tion of proteins [7-9] and cell death [10-12]. 6-OHDA-
oxidized proteins cause ER stress and upregulation of
the UPR [7,13-15], which regulates protein folding, pro-
tein degradation and protein translation.
In addition to UPR, 6-OHDA also induces ROS-
dependent apoptosis in dopaminergic cells [6,7]. Apop-
tosis is regulated by the Bcl-2 family of proteins in
which BH3-only proteins are recognized as essential
initiators of this process. In particular, the BH3-only
protein, Puma, is activated in response to a variety of
death stimuli, including DNA damage, ER stress, and
oncogene-mediated hyperproliferation [16-18]. Each of
these insults induces PUMA expression, resulting in
cytochrome-c release from the mitochondria, caspase
activation and apoptosis [17,19,20]. In addition, cells
deficient in Puma are resistant to ER stress- and DNA
damage-induced apoptosis [16,18]. These data are con-
sistent with studies suggesting that when UPR pathways
are overwhelmed apoptosis is triggered [21,22]. Thus,
Puma may provide a link between ER stress, UPR and
apoptosis.
Since 6-OHDA triggers these same pathways, we pro-
posed that Puma may mediate 6-OHDA toxicity [16-18].
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induced apoptosis in primary dissociated midbrain cul-
tures and in vivo. Using animals deficient in key DNA
damage and UPR pathway components, we also show
that toxin-mediated apoptosis is independent of the
upregulation of UPR. While UPR may be protective, the
activation of the DNA damage pathway plays a more
direct and essential role in mediating apoptosis in this
PD model.
Results
6-OHDA upregulates Puma
Previous results from our lab demonstrated that
6-OHDA causes an increase in ROS and an ROS-depen-
dent upregulation of UPR and apoptosis. Temporally,
UPR was rapidly induced within 1-3 hours, preceding
mitochondrial induction of apoptosis by 12-15 hours
[7,17]. Since PUMA has been demonstrated to be
induced by ER stress and to trigger mitochondrial events
relating to apoptosis, we sought to determine if PUMA
is transcriptionally upregulated in response to 6-OHDA.
Therefore, dissociated dopaminergic cultures were trea-
ted with 20 ¿M 6-OHDA, a dose that produces 50% loss
after 24 hours, and analyzed by RT-PCR and western
blot. Levels of Puma mRNA were significantly increased
by 9 hours after treatment with 6-OHDA (Figure 1A,
B). No increase in Puma RNA was seen in cultures pre-
treated with the anti-oxidant NAC, which we have pre-
viously demonstrated blocks 6-OHDA-induced ROS,
UPR and apoptosis [7] (Figure 1C, D). Surprisingly, even
though Puma mRNA was upregulated by 9 hours after
6-OHDA treatment, Puma protein did not significantly
increase until 24 hours (Figure 1E, F). Although the
source of this discrepancy is unclear, it is possible that
western blot sensitivity was sufficiently variable as to
prevent detection of smaller changes. These results
demonstrate that 6-OHDA induces the upregulation of
Puma in a ROS-dependent manner, suggesting that
Puma plays a role in 6-OHDA-mediated cell death.
Loss of Puma protects primary dopaminergic and non-
dopaminergic neurons against 6-OHDA
To determine if Puma plays an essential role in 6-
OHDA toxicity, dissociated dopaminergic cultures from
Puma +/+, +/- and -/- littermates were treated with or
without drug. After 24 hours, cultures were stained for
tyrosine hydroxylase (TH), a marker of dopaminergic
neurons; counting TH-positive cells showed that loss of
Puma significantly protected these neurons from cell
death (Figure 2A, B). Counting of cultures co-stained
with TH and NeuN demonstrated that Puma-deficiency
also rescued non-dopaminergic neurons (Figure 2C).
This is consistent with previous findings showing 6-
OHDA-induced cell death is not as specific to
dopaminergic neurons in vitro as it is in vivo [23].
Because many recent studies show that neurite degen-
eration is an active process distinct from that of cell
death [24], loss of neurites was also assessed. In contrast
to the survival of Puma -/- cell bodies, there was no
protection of Puma -/- neurites (Figure 2A, D). These
data indicate that Puma mediates 6-OHDA toxicity in
cell bodies, but not in neurites.
Puma deficiency protects dopaminergic neurons in vivo
against 6-OHDA
Since loss of PUMA blocked 6-OHDA-induced cell
death in cultured dopaminergic neurons, we tested
whether loss of PUMA is protective in vivo. Following a
preliminary dose response experiment (data not shown),
Figure 1 6-OHDA-triggered ROS induces upregulation of Puma.
Dissociated dopaminergic cultures derived from C57Bl/6 mice were
treated with 20 ¿M 6-OHDA and total RNA was collected at the
indicated times. A) Levels of Puma and 18S rRNA were analyzed by
RT-PCR. B) Gels in A were quantitated in ImageQuant and analyzed
by one-way ANOVA (***, p < 0.001) with Bonferroni post-tests to
compare each time point to untreated (9 hr and 12 hr: ***, p <
0.001). C) Cultures were treated with 5 mM NAC immediately prior
to treatment with 20 ¿M 6-OHDA. Total RNA was collected and
analyzed as in A. D) Gels in A were quantitated in ImageQuant and
analyzed by two-way ANOVA (6-OHDA treatment: **, p < 0.01; NAC
pre-treatment: ***, p < 0.001). E) Cell lysates were collected in RIPA
buffer at the indicated times after treatment with 20 ¿M 6-OHDA.
Protein levels were analyzed by western blotting for Puma.
Antibody specificity was confirmed by comparing blots of known
tissues positive and negative for Puma. F) Western blots in C were
quantitated in ImageQuant. Levels of Puma were normalized to
actin levels. Data were analyzed by one-way ANOVA (**, p < 0.01)
with Bonferroni post-tests to compare each time point to untreated
(24 hr: **, p < 0.01).
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were done with wild-type and Puma -/- mice. One
month later animals were sacrificed and surviving TH-
positive neurons in the SN were counted by an
unbiased stereological method to assess dopaminergic
cell survival [25]. Unbiased stereology has been widely
used to assess neuronal number in many brain regions,
including TH-positive neurons in the SN [26]. In wild-
type mice, 50% of TH-positive neurons in the SN were
lost while TH-positive neurons in the ventral tegmen-
tal area were unaffected. Although most dopaminergic
cells would have been destroyed within a week after
injection, animals were assessed at one month to
ensure stability of response and to allow for behavioral
measurements. Viability and variability proved to be
problematic in mice, however, disallowing meaningful
behavioral assessments. Loss of Puma significantly res-
cued dopaminergic neurons in the SN, indicating that
Puma is critical for 6-OHDA-induced cell loss in vivo
as well as in vitro (Figure 3A, B). Puma-deficiency also
prevented the loss of dopamine in the striata of
6-OHDA-injfinected brains, suggesting that Puma loss
also prevented dopaminergic terminal field destruction
(Figure 3C).
Puma-deficiency prevents 6-OHDA-induced apoptosis
Previously, we have shown that 6-OHDA-generated
ROS induces caspase-3 activation 12-15 hours post
treatment [7,27]. Since PUMA is known to induce apop-
tosis via activation of caspases-3 in other systems, we
Figure 2 Puma is required for 6-OHDA-induced cell death. Dissociated dopaminergic cultures derived from individual animals from Puma
+/- × Puma +/- matings were treated with 20 ¿M 6-OHDA for 24 hours. A) Cells were fixed and stained for TH. B) TH-positive cells were
counted by an unbiased stereological method and survival expressed as a percentage of untreated control. Data were analyzed by one-way
ANOVA (***, p < 0.001) with Bonferroni post-tests to compare to wild-type (+/-: **, p < 0.01; -/-: ***, p < 0.001) C) Cultures co-stained for TH and
NeuN were counted to assess the survival of non-DA neurons. Data were analyzed by Student’s t-test (**, p < 0.01) D) TH-positive neurite length
was estimated by an unbiased stereological method. Data were analyzed by Student’s t-test (ns).
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whether loss of Puma prevents caspase-3 cleavage after
6-OHDA treatment. Immunofluorescent analysis fol-
lowed by unbiased counting of cultures prepared from
either Puma +/+ or -/- animals revealed that the per-
centage of TH neurons that were positive for cleaved
caspase-3 prior to toxin treatment was unchanged in
Puma -/- cultures (Figure 4A, B), while cleaved caspase-
3 positive neurons increased threefold in Puma +/+ cul-
tures (Figure 4A, B). Western blotting confirmed that
Puma +/+ cultures exhibited a large increase in the
levels of cleaved caspase-3 at 24 hours, while Puma -/-
cultures did not (Figure 4C, D). These results indicate
that Puma is required for the activation of caspase-3 in
dopaminergic neurons in response to 6-OHDA.
Activation of UPR Markers is unaffected by Puma-
deficiency
If Puma serves as a link between UPR and the mito-
chondrial induction of apoptosis, then early events of
UPR, such as ATF3 induction and Xbp-1 splicing,
should not be affected by Puma-deficiency. Accordingly,
early UPR events will be upregulated by 6-OHDA in
both Puma +/+ and Puma -/- cultures. As predicted,
ATF3 RNA and protein levels were increased to a simi-
lar extent in both Puma +/+ and -/- cultures 3 hours
Figure 3 Puma is required for 6-OHDA-induced loss of DA neurons in the SN and striatal DA depletion.C 5 7a n dPuma -/- mice were
treated with 6-OHDA by unilateral intrastriatal injection and sacrificed one month later. A) 50 ¿M sections were stained for TH. Pictures are
representative images of the SN ipsilateral to injection site. Locations of SN and ventral tegmental area (VTA) are indicated in the first panel.
B) TH-positive cells were counted, ipsilateral to contralateral ratios were calculated and survival was expressed as a percentage of untreated
control. Data were analyzed by two-way ANOVA (treatment: **, p < 0.01; genotype: **, p < 0.01). Results of Bonferroni post-tests are indicated
on graph (***, p < 0.001). C) Striata were lysed and DA levels were analyzed by HPLC with electrochemical detection. Ipsilateral to contralateral
ratios were calculated and expressed as a fraction of untreated control. Data were analyzed by two-way ANOVA (treatment: **, p < 0.01;
genotype: ns). Results of Bonferroni post-tests are indicated on graph (*, p < 0.05).
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deficiency also had no effect on 6-OHDA-mediated
induction of Xbp-1 splicing or the overall levels of Xbp-
1 (Figure 5D, data not shown). Consistent with the pro-
posed model, these early UPR markers are induced by
6-OHDA regardless of Puma status indicating that they
are not downstream of Puma.
The timing of PUMA upregulation suggests that it is
either upstream of or parallel to the induction of late
UPR markers. Therefore, we assessed the expression of
late UPR markers in Puma +/+ and -/- cultures 9 hours
after 6-OHDA treatment, a time point at which these
markers are significantly upregulated [7,27]. RNA pre-
pared from either PUMA wild type or null dopaminer-
gic cultures showed that markers representing all 3
branches of the UPR pathway (C H O P ,B i P ,G A D D 3 4 ,
and p58
IPK) were upregulated to a similar extent in
response to toxin regardless of genotype (Figure 5E).
Consistent with the qPCR results, the UPR marker
CHOP was increased in the nuclei of dopaminergic neu-
rons following toxin treatment in both Puma +/+ and
-/- cultures (Figure 5F, G). Collectively, these data sug-
gest that loss of Puma does not significantly affect the
UPR pathway.
Loss of ATF3 does not protect cells against 6-OHDA
The transcription factor ATF3 is rapidly induced in
response to ER stress and is a key mediator of the PERK
branch of the UPR pathway [28]. Since ATF3 levels
increase dramatically in response to 6-OHDA (> 30-fold)
[7,27] and the levels of various UPR markers are unaf-
fected by loss of Puma, we sought to determine if
6-OHDA-mediated UPR was playing a direct role in the
death of these neurons using ATF3-deficient mice [29].
Dissociated dopaminergic cultures from ATF3 +/+ and
-/- mice were treated with or without 6-OHDA for
24 hours before being evaluated for surviving TH-positive
cells. Loss of ATF3 did not protect cells or neurites
against 6-OHDA (Figure 6A, B, data not shown).
We also found that 6-OHDA-induced caspase-3 cleavage
in dopaminergic neurons regardless of the ATF3 geno-
type (Figure 6C). These results indicate that ATF3 is not
Figure 4 Puma mediates caspase-3 activation following 6-OHDA treatment. Dopaminergic cultures derived from Puma +/+ and Puma -/-
animals were treated with 20 ¿M 6-OHDA. A) Cultures were fixed and stained at 0 or 24 hours for TH and cleaved caspase-3 (a-caspase-3). B)
TH-positive and cleaved caspase-3-positive cells were counted and the percentage of TH-positive cells that were also cleaved caspase-3 positive
was calculated. Data were analyzed by two-way ANOVA (treatment: **, p < 0.01; genotype: *, p < 0.05). C) Cell lysates were collected in RIPA
buffer 24 hours after treatment with 20 ¿M 6-OHDA. Protein levels were analyzed by western blotting for cleaved caspase-3 and actin. D)
Western blots in C were quantitated in ImageQuant. Levels of cleaved caspase-3 were normalized to actin levels. Data were analyzed by two-
way ANOVA (treatment: **, p < 0.01; genotype: *, p < 0.05).
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that UPR does not play a direct role in the induction of
apoptosis by 6-OHDA.
In addition, we tested whether Puma expression levels
were altered in the ATF3-deficiency model. Consistent
with the sensitivity of ATF3 -/- dopaminergic neurons
to 6-OHDA, Puma was upregulated to the same extent
in both wild-type and ATF3-deficient cultures in
response to neurotoxin treatment (Figure 6D). Because
CHOP is upregulated by all three branches of the UPR
pathway including the PERK/ATF3 branch [21], we
directly assessed CHOP levels in dopaminergic neurons
derived from ATF3 +/+ or ATF3 -/- animals. CHOP
was still induced in the ATF3-deficient animals, albeit to
a lesser extent (Figure 6E, F). That this was only a par-
tial reduction is not surprising since IRE1 and ATF6
also induce CHOP [30]. These data indicate that ATF3
deficiency does not affect 6-OHDA-induced cell loss
Figure 5 Loss of Puma does not alter the activation of UPR
markers. Dopaminergic cultures derived from Puma +/+ and -/-
animals were treated with 20 ¿M 6-OHDA. A) Total RNA was isolated
at the indicated times and ATF3 and GAPDH RNA levels were
analyzed by qPCR. ATF3 levels were normalized to GAPDH levels.
B) Cell lysates were collected in RIPA buffer at the indicated times
and protein levels were analyzed by western blotting for ATF3 and
actin. C) Western blots in B were quantitated in ImageQuant. Levels
of ATF3 were normalized to actin levels. Data were analyzed by
two-way ANOVA (treatment: **, p < 0.01; genotype: ns). D) Total RNA
was isolated at the indicated times and Xbp-1 RNA levels were
analyzed by semi-quantitative RT-PCR. Data were analyzed by two-
way ANOVA (treatment: ***, p < 0.001; genotype: ns). E) Total RNA
was isolated 9 hours after treatment and RNA levels of the indicated
genes were analyzed by qPCR. Data are shown as fold change over
untreated control and were analyzed by two-way ANOVA. CHOP
(treatment: ***, p < 0.001; genotype: ns), BiP (treatment***, p < 0.001;
genotype: ns), GADD34 (treatment: **, p < 0.01; genotype: ns), p58IPK
(treatment: **, p < 0.01; genotype: ns). F) Cells were fixed 24 hours
after treatment and stained for TH and CHOP. G) TH-positive and
CHOP-positive cells were counted and the percentage of TH-positive
cells that were also CHOP-positive was calculated. Data were
Figure 6 ATF3 is not required for 6-OHDA-induced cell death.
Dopaminergic cultures prepared from ATF3 +/+ and -/- mice were
treated with 20 ¿M 6-OHDA. A) 24 hours after treatment, cultures
were fixed and stained for TH. B) TH-positive cells were counted
and survival expressed as a percent of untreated control. Data were
analyzed by Student’s t-test (ns). C) Twenty four hours after
treatment, cells were fixed and stained for TH and cleaved caspase-3
(a-caspase-3). TH-positive and a-caspase-3 positive cells were counted
and the percentage of TH-positive cells that were also a-caspase-3-
positive was calculated. Data were analyzed by two-way ANOVA
(treatment: ***, p < 0.001; genotype: ns). D) Total RNA was isolated at
the indicated times and Puma and 18S rRNA RNA levels were assayed
by RT-PCR. Data were analyzed by two-way ANOVA (treatment: ***,
p < 0.001, genotype: ns). E) Cells were fixed 24 hours after treatment
and stained for TH and CHOP. F) TH-positive and CHOP-positive cells
were counted and the percentage of TH-positive cells that were also
CHOP-positive was calculated. Data were analyzed by two-way
ANOVA (treatment: ***, p < 0.001; genotype: *, p < 0.05).
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ing that prolonged 6-OHDA-mediated CHOP upregula-
tion does not result in apoptosis.
6-OHDA leads to DNA damage and activation of p53
Since activation of UPR does not appear to mediate cell
death in response to 6-OHDA, we sought to determine
how PUMA is upregulated in this model. Since ROS
can induce DNA damage in addition to protein damage,
we determined if 6-OHDA-generated ROS induces the
latter by assessing levels of poly (ADP-ribose) (PAR) in
dissociated dopaminergic cultures. PAR is synthesized
by the nuclear DNA repair enzyme PAR polymerase in
response to DNA strand breaks [31,32]. Within 15 min-
utes of 6-OHDA treatment, PAR staining in dopaminer-
gic neurons was dramatically increased and was blocked
by NAC (Figure 7A, B). These results indicate that 6-
OHDA causes ROS-mediated DNA damage in a time-
frame that precedes protein oxidation [7].
Ataxia telangiectasia-mutated kinase (Atm) and the
Atm and Rad53-related kinase (Atr) are activated by
phosphorylation in response to many DNA damage
agents [33,34]. Therefore, we determined the phosphor-
ylation state of Atm and Atr following treatment with
6-OHDA. Within 1 hour, 6-OHDA induced phosphory-
lation of Atr, but not Atm (Figure 7C).
Since Puma is a known transcriptional target of the
p53 transcription factor and p53 is a target of ATR, we
tested whether p53 was activated by 6-OHDA. Phos-
phorylation of p53 at Ser15 (p-p53) is known to be
induced by DNA damage and leads to its accumulation
and activation of transcriptional targets [35]. Western
blot analysis demonstrated that 1 hour after 6-OHDA
exposure, there is a significant increase in p-p53 levels,
but not in overall p53 protein levels, in toxin-treated
versus untreated cultures (Figure 7D, E). Immunocyto-
chemistry revealed that p-p53 is localized primarily in
the nucleus where it can activate transcription of its tar-
get genes (Figure 7F). Loss of Puma had no effect on
phosphorylation of p53, which is consistent with a
model that places p53 upstream of Puma (Figure 7D-F).
Taken together, these data suggest that 6-OHDA-gener-
ated ROS rapidly activates the DNA damage repair
pathway in dissociated DA cultures.
p53-deficiency protects cell bodies and neurites against
6-OHDA
To determine if p53 plays a critical role in 6-OHDA-
induced cell death, dissociated dopaminergic cultures
were prepared from p53 +/+, +/- and -/- littermates and
treated with or without 6-OHDA for 24 hours prior to
counting TH-positive neurons. In p53 +/+ cultures,
6-OHDA led to the loss of 50% of both TH-positive cell
bodies and neurites; however, in p53 -/- cultures, only
15% of TH-positive cell bodies and 20% of TH-positive
neurites were lost (Figure 8A-C). Non-dopaminergic
cells in p53 -/- cultures were also protected against
6-OHDA, again confirming findings that 6-OHDA-
induced cell death is less specific in vitro (data not
s h o w n )[ 2 3 ] .T h u s ,l o s so fp53 protects cell bodies and
neurites against 6-OHDA and p53 is required for
6-OHDA-induced apoptosis.
Consistent with studies showing that Puma is a tran-
scriptional target of p53, PUMA was not induced in
p53-null cultures, but was significantly upregulated in
p53 +/+ cultures (Figure 8D). Finally, to determine if
the activation of p53 by 6-OHDA is distinct from the
6-OHDA-induced upregulation of UPR, CHOP levels
were assessed in p53 +/+ and -/- cultures. Following
6-OHDA treatment, CHOP mRNA and protein levels
Figure 7 6-OHDA leads to activation of the DNA damage
repair pathway. Primary cultures prepared from Puma +/+ and -/-
mice were treated with 20 ¿M 6-OHDA. A) Cultures were fixed
30 minutes after treatment and stained for TH and PAR. B) Cultures
treated for 15 minutes, 30 minutes, or 30 minutes with 5 mM NAC
pretreatment were fixed and stained for TH and PAR. TH-positive
and PAR-positive cells were counted and the percentage of TH-
positive cells that were also PAR-positive was calculated. Data were
analyzed by one-way ANOVA (***, p < 0.001) with Bonferroni post-
tests to compare each treatment to untreated (15 m: **, p < 0.01;
30 m: ***, p < 0.001). C and D) Cell lysates were collected in RIPA
buffer at the indicated times and proteins levels were assessed by
western blotting for p-Atm, p-Atr, p-p53, p53 and actin. E) Western
blots in D were quantitated with ImageQuant. Levels of p-p53 were
normalized to total p53 levels. Data were analyzed by two-way
ANOVA (treatment: *, p < 0.05; genotype: ns). F) Cultures treated for
1 hour with 6-OHDA were fixed and stained for TH and p-p53.
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derived from p53 +/+ and -/- mice (Figure 8E, F).
Taken together, these data suggest that UPR is not
downstream of p53 in this model and that the activation
of p53 and upregulation of UPR represent two distinct
responses to 6-OHDA.
Discussion
Many PD-linked mutations are associated with protein
aggregation and Lewy body formation, underscoring the
role of aberrant protein handling in this disorder
[36,37]. Although previous results established that
6-OHDA-triggered ER stress results in UPR, whether
UPR and cell death are sequential or parallel events was
not determined [7,27]. Here, we demonstrate that Puma
is required for 6-OHDA-induced cell death both in vitro
and in vivo. The loss of Puma blocks the induction of
apoptosis but has no effect on the activation of UPR,
suggesting that UPR and apoptosis are parallel events
induced by 6-OHDA (Figure 9). In support of this,
Figure 8 p53 is required for 6-OHDA-induced cell death. Primary cultures from individual pups from p53 +/- × p53 +/- matings were treated
with 20 ¿M 6-OHDA. A) After 24 hours, cultures were fixed and stained for TH. B) TH-positive neurons were counted and survival was expressed
as a percent of untreated control. Data were analyzed by one-way ANOVA (***, p < 0.001) with Bonferroni post-tests to compare to wild-type
(-/-, **, p < 0.01). C) TH-positive neurite length was estimated using unbiased stereology and expressed as a percent of untreated control. Data
were analyzed by Student’s t-test (*, p < 0.05). D) Total RNA was isolated at the indicated times and Puma and 18S rRNA RNA levels were
analyzed by semi-quantitative RT-PCR. Data were analyzed by two-way ANOVA (treatment: **, p < 0.01; genotype: *, p < 0.05). E) Total RNA was
isolated at the indicated times and CHOP and GAPDH RNA levels were analyzed by qPCR. Data were analyzed by two-way ANOVA (treatment:
***, p < 0.001; genotype: ns). F) Cells treated for 24 hours were co-stained for TH and CHOP. TH-positive and CHOP-positive cells were counted
and the percentage of TH-positive cells that were also CHOP-positive was calculated. Data were analyzed by two-way ANOVA (treatment: ***, p
< 0.001; genotype: ns). 11
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not required for 6-OHDA-induced cell death. Instead,
the DNA damage repair pathway is critical since loss of
p53 or Puma prevents cell death during toxin treatment.
Puma is required for 6-OHDA-induced cell death
We have demonstrated that Puma is required for
6-OHDA-induced caspase activation and cell death. In
other systems, upregulation of Puma leads to cyto-
chrome-c release and caspase activation [38,39]. Release
of cytochrome-c from the mitochondria is an essential
step to the activation of executioner caspases and apop-
tosis. Previously, we used subcellular fractionation and
western blotting to demonstrate that 6-OHDA treat-
ment leads to cytochrome-c redistribution and loss in
primary cultures [7]. However, obtaining sufficient
material for this method is not feasible when comparing
two genotypes given the necessity of acquiring very
large numbers of timed pregnant animals to isolate
adequate amounts of mesencephalic tissue of each
genotype. Alternatively, we sought to assess cyto-
chrome-c release by immunocytochemistry. However,
while loss of cytochrome-c staining reportedly repre-
sents cytochrome-c release in some systems [39], this
was not true in dopaminergic neurons in primary cul-
ture since changes in staining did not mirror our subcel-
lular fractionation and western blotting results
(Additional File 1, Figure S1). Nevertheless, caspase-3
activation was not observed in Puma -/- neurons indi-
cating that Puma is upstream of this executioner step in
dopaminergic neurons (Figure 4).
6-OHDA-induced UPR does not mediate cell death
UPR is thought to activate both adaptive and apoptotic
pathways, depending on the severity and duration of ER
stress [22,40]. Pro- and anti-apoptotic proteins, such as
Bcl-2, Bax and Bak, can also directly regulate UPR pro-
teins, reinforcing the concept that UPR is a complex,
highly regulated process intimately tied to cellular
homeostasis as well as apoptosis [41]. Over the time
course of 6-OHDA-triggered cell death, however, UPR
appears to be primarily adaptive. The persistent activa-
tion of UPR even though the cells are protected from
cell death suggests that UPR is not mediating cell death
in this model. Conceivably, UPR might induce apoptosis
in Puma deficient neurons over a longer time frame
(2-3 days). However, in wild type cultures, UPR signal-
ling pathways may still be protective while 6-OHDA
induces p53/Puma-dependent cell death within 24
hours.
UPR is regulated by three interconnected pathways
mediated by PERK, IRE1 and ATF6. The PERK arm of
the UPR pathway triggers a cascade of transcription fac-
tors stemming from the phosphorylation of eIF2¿. ATF4
is immediately downstream, followed by ATF3 and then
CHOP [42,43]. If PERK signalling were inducing cell
death in dopaminergic neurons, then loss of ATF3
would have protected these cells from 6-OHDA. How-
ever, loss of ATF3 did not prevent 6-OHDA-mediated
upregulation of Puma, caspase-3 activation or cell death
even though, as expected, ATF3-deficiency reduced the
upregulation of CHOP (Figure 6). Since loss of ATF3
reduced CHOP induction without affecting cell death or
PUMA activation, this pathway is likely adaptive and
distinct from the PUMA-cell death pathway.
The IRE1 and ATF6 branches of UPR also appear to
be primarily adaptive in the 6-OHDA model. IRE1 is
thought to activate the JNK pathway [44] and pharma-
cological inhibitors of JNK were ineffective against
6-OHDA (A. Bernstein and W. Holtz, unpublished
observations) [27]. IRE1 can also regulate Bcl-2 family
members [45]; however, neither the targeted over-
expression of Bcl-2 in DA neurons nor Bax deficiency
rescued cells from 6-OHDA-mediated apoptosis [46].
Figure 9 Model of Puma action in response to 6-OHDA. In this
model, 6-OHDA-induced ROS production causes both DNA and
protein damage. Oxidative protein damage activates UPR, leading to
the upregulation of chaperones. DNA damage leads to the
activation of the p53 DNA damage repair pathway and p53-
mediated Puma upregulation leads to the induction of apoptosis.
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that this pathway is playing a role since temporally
CHOP and Puma are induced at the same time point [7].
Finally, the loss of Puma had no effect on any of the
UPR branches as splicing of Xbp-1 and the upregulation
of ATF3, BiP, CHOP, GADD34,and p58
IPK occurred in
both Puma +/+ and Puma -/- cultures (Figure 5). These
data suggest that the entire UPR network is parallel to
Puma. One caveat to this interpretation is a study
demonstrating protection against 6-OHDA in CHOP
knockout mice [47]. However, CHOP can be upregulated
by a variety of cellular insults and may have been induced
by distinct mechanisms owing in part to the chosen dos-
ing paradigm. Moreover, the authors were unable to
detect upregulation of other UPR markers [47].
6-OHDA induces cell death through the DNA damage
repair pathway
Using DNA fragmentation assays or TUNEL staining,
we previously demonstrated single strand DNA breaks
18-24 hours after 6-OHDA treatment suggesting DNA
oxidation was a late event (Holtz, Kim-Han, and O’Mal-
ley, unpublished observations) [48]. However, these
methodologies lack the sensitivity to measure rapidly
occurring changes in DNA structure. In contrast, anti-
bodies directed against PAR, phosphorylated Atr and
p53 revealed very rapid changes to the DNA damage
repair pathway (Figure 7). These findings are consistent
with results from other cell systems demonstrating that
p53 is required for 6-OHDA-induced cell death (Figs.
7,8) [49,50]. Loss of p53 also prevents the upregulation
of Puma, indicating that p53 is upstream of Puma in
this system (Figure 9). In contrast, the UPR marker,
CHOP, is unaffected by the loss of p53, providing
further evidence that 6-OHDA-induced apoptosis and
UPR represent parallel processes. These findings are in
agreement with previous results demonstrating the acti-
vation of p53 by 6-OHDA and protection by inhibitors
of p53 against 6-OHDA [49,50].
Cell body loss and neurite loss are separate processes in
dissociated DA neuron
New data suggest that axonal impairment may play an
early, critical role in PD. Hence, loss of neurites and cell
bodies may occur by molecularly distinct programs [24].
Results from the dissociated midbrain cultures support
this notion as loss of p53 protects both cell bodies and
neurites, whereas loss of PUMA protects only cell bodies
(Figure 2, data not shown). This suggests that the path-
way splits downstream of p53. PUMA mediates death of
t h ec e l lb o d ya n das e p a r a t ep 5 3 - d e p e n d e n tp a t h w a yi s
responsible for loss of neurites. In vivo, however, loss of
Puma protected both the SN cell bodies and DA
innervation of the striatum (Figure 3). Additional studies
are underway to understand these differences.
Conclusions
Taken together, the results of the present study suggest
that the activation of UPR does not mediate cell death
but may represent a protective mechanism employed by
dopaminergic neurons in response to 6-OHDA-induced
protein damage. Instead, DNA damage may lead to acti-
vation of a p53- and Puma-dependent apoptotic cascade.
T h e r ei sal a r g eb o d yo fe v i d e n c es u p p o r t i n gb o t ht h e
activation of UPR pathways and p53-dependent path-
ways in toxin models of PD and PD itself. Therefore,
elucidating which of these mechanisms is protective and
which leads to cell death will help in developing better
interventions for PD.
Methods
Animals
Animals were treated in accordance with the National
Institutes of Health G u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals. Wild-type C57/Bl6 mice were
from Charles River Laboratories (Wilmington, MA).
Puma knockout mice were previously generated and
characterized [16]. ATF3 knockout mice were gener-
ated and provided by Dr. Tsonwin Hai (Ohio State
University) [29]. p53 knockout mice were provided by
Dr. Helen Piwnica-Worms (Washington University
Medical School) [51].
6-OHDA injections
Injections of 10 ¿g 6-OHDA were done as described
using the coordinates A 1.0, L 2.5 mm [52]. 6-OHDA
was dissolved in N2-bubbled water at a concentration of
5 ¿g/¿l and injected at a rate of 0.5 ¿l/min for 4 m. Mice
were sacrificed one month after injection and brains were
removed for analysis. Preliminary experiments demon-
strated that this dose produced ~50% loss of dopaminer-
gic neurons in the SN 1 month after injection.
Tissue preparation
After removal of the brain, striata were dissected and
the remaining brain was fixed and cryoprotected as
previously described [53]. Striata were immediately
homogenized for high-pressure liquid chromatography
(HPLC) [53]. Coronal sections (50 ¿M) spanning
the SN (A - 2.8 to -3.8) were cut on a microtome for
immunocytochemistry.
Immunohistochemistry and stereology
Every fourth SN section was stained with sheep polyclo-
nal anti-TH antibody (1:2000, Novus Biologicals, Little-
ton, CO) followed by Alexa 488 conjugation secondary
Bernstein et al. Molecular Neurodegeneration 2011, 6:2
http://www.molecularneurodegeneration.com/content/6/1/2
Page 10 of 13(1:1000, Molecular Probes, Eugene, OR). Sections were
mounted and coverslipped with Vectashield with DAPI
(Vector Labs, Burlingame, CA). StereoInvestigator soft-
ware (MicroBrightField, Williston, VT) was used to
perform unbiased stereological counts of TH immu-
noreactive cell bodies in the SNpc using the optical
fractionator method [25]. Counting was performed
with a 63x oil objective. The estimated total number of
TH neurons was calculated based on the following
formula: N = Q
- ×1/ssf × 1/asf × t/h, where N is the
estimate of the total number of cells, Q
- is the number
of objects counted, ssf is the section sampling fraction,
asf is the area sampling fraction, and t/h is the actual
section thickness divided by the height of the dissector.
Gundersen (m = 1) coefficients of error were less than
0.1. The number of cells on the side ipsilateral to the
injection was compared to the number of cells on the
contralateral side by calculating the ipsilateral to contral-
ateral ratio. For imaging, sections were stained with
mouse monoclonal anti-TH antibody (1:5000, Millipore,
Billerica, MA) with DAB detection (Vector Labs). Sec-
tions were mounted and coverslipped with Vectashield
(Vector Labs). Images were acquired on a Nikon 90i
with Volocity software (Improvision, Waltham, MA).
Dopamine measurements
Striatal lysates were processed as described [53], diluted
in MD-TM mobile phase (ESA, Chelmsford, MA) and
separated on an ESA MD-150 column with a Coulo-
chem III and EZChromElite software (ESA). Samples
were analyzed in triplicate; ipsilateral to contralateral
ratios were calculated.
Cell culture
Embryonic day 14 (E14) CF1 murine midbrains (Charles
River Laboratories, Wilmington, MA, USA) were pre-
pared as described [6]. To assess survival of neurons
after 6-OHDA treatment, mice heterozygous for Puma
or p53 were mated to produce wild type, heterozygous,
and homozygous deficient embryos. Cultures were
derived from individual pups and pups were individually
genotyped. Comparisons were performed between litter-
mates. Due to the limited amount of tissue harvested
from individual pups, all other experiments were per-
formed by mating homozygous knockout animals or
wild-type animals and pooling tissue from all pups in
each litter. After seven days in vitro, cells were treated
with 20 ¿M 6-OHDA, a dose that produces 50% loss of
dopaminergic neurons 24 hours after treatment.
Reverse Transcription PCR
Dissociated midbrain neurons were plated in 12-well
plates, treated with 6-OHDA and/or pretreated with
N-acetyl cysteine (NAC; Sigma). Cultures were washed
with PBS, total RNA was extracted (RNeasy Mini Kit;
Qiagen, Valencia, CA) and then reverse transcribed
(High Capacity cDNA Reverse Transcription Kit;
Applied Biosystems, Foster City, CA). Levels of Puma,
Xbp-1 and 18S rRNA were analyzed by semi-quantita-
tive reverse transcription PCR (RT-PCR) using pri-
mers specific for the gene of interest. PCR products
were resolved with polyacrylamide gel electrophoresis,
visualized (SYBR Safe DNA; Invitrogen) and image
(Storm PhosphorImager; Molecular Dynamics, Piscat-
away, NJ). Band intensities were measured (Image-
Quant; Amersham Biosciences, Piscataway, NJ) and
Puma and Xbp-1 levels were normalized to 18S rRNA
levels and then compared to levels in untreated sam-
ples. Levels of ATF3, CHOP, BiP, GADD3, p58
IPK and
GAPDH were determined by quantitative real-time
PCR (qPCR). cDNAs were amplified with Power SYBR
Green PCR Master Mix (Applied Biosystems) using
gene-specific primers (Table 1). Detection was per-
formed with the Applied Biosystems Prism 7000. All
PCR reactions were done in triplicate. All genes were
normalized to GAPDH and compared to untreated
samples.
Western blotting
Dissociated midbrain neurons were plated in 48-well
plates and treated as described above for RT-PCR experi-
ments. Lysates were collected and prepared as described
[7]. Rabbit polyclonal antibodies against p-p53 (Ser15),
p-ATR (Ser428), p-ATM (Ser1981), p-eIF2¿ (Ser51),
cleaved caspase-3 and HRP-linked anti-rabbit antibodies
were from Cell Signaling Technologies (Beverly, MA).
Table 1 Primers for Reverse Transcription PCR
Gene Primer 1 Primer 2
18s rRNA 5’-GGGAACGCGTGCATTT
ATCAG-3’,
5’-CGCTATTGGAGCTGGA
ATTAC-3’
ATF3 5’-TGCCAAGTGTCGAAACAA
GAA-3’
5’-CGGTGCAGGTTGAGC
ATGTA-3’
BiP 5’-CTTCAATGATGCCC
AGCGA-3’
5’-CCAGGCCATATGCAATAG
CAG-3’
CHOP 5’-TATCTCATCCCCA
GGAAACG-3’
5’-GATGTGCGTGTGAC
CTCTGT-3’
GADD34 5’-GAGATTCCTCTAAAAGC
TCGG-3’
5’-CAGGGACCTGGACGG
GCAGC-3’
GAPDH 5’-TGCCCCCATGTTTGT
GATG-3’
5’-TGTGGTCATGAGCC
CTTCC-3’
p58
IPK 5’-TCCTGGTGGACCTGCA
GTACG-3’
5’-CTGCGAGTAATTTCTT
CCCC-3’
Puma 5’-ACGACCTCAACG
CGCAGTA-3’
5’-CTAGTTGGGCTCCATT
TCTGG-3’
Xbp-1 5’-TAGAAAGAAAGCCC
GGATGA-3’
5’-CTCTGGGGAAGGA
CATTTGA-3’
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CHOP/Gadd153 were from Santa Cruz Biotechnologies
(Santa Cruz, CA). Rabbit polyclonal anti-Puma, mouse
anti-actin and HRP-linked anti-mouse antibody were from
Sigma (Saint Louis, MO). Mouse monoclonal anti-p53 was
from EMD Biosciences (San Diego, CA). Specific protein
bands were detected and analyzed by chemiluminescence
substrate detection and quantitative fluoroimaging as pre-
viously described [7].
Immunocytochemistry
Dissociated midbrain neurons were plated and fixed as
described [6]. Cultures were stained with sheep polyclo-
nal anti-tyrosine hydroxylase (TH) (Novus Biologicals,
Littleton, CO) and Alexa488 ¿-sheep (Molecular Probes,
Carlsbad, CA). Cultures were co-stained for various
markers using the following antibodies: mouse monoclo-
nal ¿-NeuN (Chemicon, Billerica, MA), cleaved caspase-
3, mouse monoclonal ¿-cytochrome-c (Promega, Madi-
son, WI), mouse monoclonal ¿-CHOP (Santa Cruz),
¿-p-p53 or mouse monoclonal ¿-Poly (ADP-Ribose)
(PAR; Alexis Biochemicals, San Diego, CA). Cy3-conju-
gated secondary antibodies were purchased from Jack-
son Labs (Bar Harbor, ME). In all cases cells were
counted using unbiased stereological methods (Stereo
Investigator, MicroBrightField, Williston, VT). The esti-
mated total number of TH neurons in the culture dish
was calculated based on the following formula: N = Q
-
×1/ssf × 1/asf, where N is the estimate of the total num-
ber of cells, Q
- is the number of objects counted, ssf is
the section sampling fraction and asf is the area sam-
pling fraction. Gundersen (m = 1) coefficients of error
were less than 0.1. TH-positive neurite length was esti-
mated by an unbiased stereological method (Petri-
metrics, Stereo Investigator). Images were acquired by
confocal microscopy (Olympus Fluoview 500, Olympus,
Center Valley, PA) and processed in ImageJ.
Statistical analysis
GraphPad Prism software (San Diego, CA) was used for
statistical analysis. All data were collected from a mini-
mum of three independent experiments. The signifi-
cance of effects between control and drug treatment
conditions was determined by Student’st - t e s to ro n e -
way ANOVA with Bonferroni Multiple Comparisons
tests. The significance of effects between genotypes and
drug treatment conditions was determined by two-way
ANOVA with Bonferroni post-tests.
Additional material
Additional file 1: Figure S1: Loss of cytochrome-c detected by
immunocytochemistry does not parallel redistribution of
cytochrome-c detected by fractionation and western blotting.
Cultures derived from Puma +/+ and -/- animals were treated with
20 ¿M 6-OHDA for 18 h. A) Cells were fixed and stained for TH and
cytochrome-c. B) Images were analyzed in ImageJ to determine the
area of cytochrome-c staining over threshold in TH-positive neurons.
Data was analyzed by two-way ANOVA (treatment: ***, p < 0.001;
genotype: ns).
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